Kate E. Broderick

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 689 citations

Immunology, Human Papillomavirus 16, Cancer-associated Virus +17

Immunogenicity of a DNA vaccine candidate for COVID-19

Trevor R.F. Smith, Ami Patel, Stephanie Ramos et al. · Nature Communications · 2020 · 635 citations · Full text

Immunotherapy Against HPV16/18 Generates Potent T _H 1 and Cytotoxic Cellular Immune Responses

Mark L. Bagarazzi, Jian Yan, Matthew P. Morrow et al. · Science Translational Medicine · 2012 · 279 citations · Full text

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas, ShuPing Yang, Jean Boyer et al. · EClinicalMedicine · 2020 · 276 citations · Full text

Two nitridergic peptides are encoded by the gene<i>capability</i>in<i>Drosophila melanogaster</i>

Laura Kean, William Cazenave, Laurence Costes et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2002 · 226 citations